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Abstract: The current global pandemic of coronavirus disease 2019 (COVID-19) has 
affected over 21 million people and caused over half a million deaths within a few months. 
COVID-19 has become one of the most severe public health crises in recent years. 
Compared to other pathogenic coronaviruses, the severe acute respiratory syndrome cor-
onavirus 2 (SARS-CoV-2) is highly infectious. Due to the lack of specific and effective 
treatment or vaccines, disease prevention and early detection are essential for establishing 
guidelines to mitigate further spread. The potential role of the ocular system in COVID-19 
is still not clear but it has gained increasing attention. Here, we reviewed both clinical and 
research evidence on the ocular manifestations associated with COVID-19, the presence of 
SARS-CoV-2 in ocular surface tissues and tears, and the potential role of the eye in 
contracting SARS-CoV-2. 
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SARS-CoV-2 and COVID-19
The initial outbreak of the global pandemic of coronavirus disease 2019 (COVID-19) 
was found in Wuhan, China in December 2019, which was later discovered to be 
caused by the novel coronavirus SARS-CoV-2.
Until August 2020, about 21 million COVID-19 cases have been reported 
worldwide with about 0.7 million deaths (https://www.who.int/emergencies/dis 
eases/novel-coronavirus-2019). COVID-19 is characterized by a range of symp-
toms, including influenza-like illness with fever, cough, dyspnea, headache and 
myalgia in most cases, as well as potentially lethal respiratory infections and acute 
respiratory distress syndrome in severe cases.1 The incubation period of SARS- 
CoV-2 is about 3 to 7 days. Approximately 80% of the patients have mild 
symptoms or are asymptomatic, 15% are severe requiring oxygen, and 5% are in 
critical condition requiring ventilator support.2
Coronaviruses (CoVs) are a family of single-stranded, positive RNA viruses 
characterized by spike proteins projecting from their envelopes.3 The coronavirus 
family has four subgroups (α, β, γ, and δ), of which the β subgroup contains 3 
highly infectious viruses: SARS-CoV, MERS-CoV, and SARS-CoV-2.4 These 
viruses bind to host cell surface receptors (e.g. ACE2) using these spike proteins, 
fuse their viral envelope with the host cell membrane, and then enter the cell.5 
Viral RNA uses the host cell for RNA replication, protein synthesis, as well as 
assembly and release of new viral particles. CoVs cause a variety of diseases in 
non-human species including birds and livestock, as well as mild to lethal 
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respiratory diseases in humans.6 SARS-CoV and MERS- 
CoV caused outbreaks in 2002/2003 and 2012/2013, and 
studies indicated that their transmission is primarily 
through respiratory droplets, aerosols, close contacts, 
fecal-oral spread, and possibly the eye.7 Similarly, 
SARS-CoV2 has been reliably detected using RT-PCR 
in nasopharyngeal and oropharyngeal secretions, and it is 
also detectable in blood and stool samples.8
Since an effective therapeutic agent or vaccine is not 
yet available for SARS-CoV-2, it is important to under-
stand the potential risks of each transmission modality in 
order to establish proper preventative measures. Current 
CDC guidelines recommend protecting the nose, mouth, 
and eye because they contain susceptible mucous mem-
branes, which is based on the experience from previous 
SARS/MERS epidemics (https://www.cdc.gov/corona 
virus/2019-ncov/index.html). Here, we provided 
a narrative review of current evidence to summarize and 
speculate the role of the ocular system in SARS-CoV-2 
transmission.
Methodology
A literature search was performed using 4 databases 
(PubMed, Web of Science, Scopus, and Google Scholar) 
which returned studies published up to July 31st, 2020. 
Keywords included “COVID-19”, “SARS-CoV-2”, “eye”, 
“ocular”, “ophthalmic”, “ACE2” and MeSH terms 
(“COVID-19”, “severe acute respiratory syndrome coro-
navirus 2” and “Eye”). For this review, relevant studies 
that emphasized ocular manifestations of COVID-19 or 
SARS-CoV-2, viral detection of SARS-CoV-2 in ocular 
surface secretions or tears, and ACE2 presence in ocular 
tissues were included. Letters, editorials, case reports, case 
series, observational studies, reviews, meta-analyses, and 
systematic reviews were included in the literature search.
Ocular Manifestations of COVID-19
The prevalence of ocular manifestations of COVID-19 
varies. According to our literature survey, it ranged from 
0% to 32% (Table 1). However, several studies suggested 
that the prevalence of ocular signs and symptoms in 
COVID-19 patients is relatively low.9 Two separate meta- 
analyses on ocular manifestations estimated a pooled pre-
valence of 5.5% and <4%.10,11 Another meta-analysis 
showed that the prevalence of conjunctivitis in 1167 
COVID-19 patients was about 1%.12 Interestingly, the 
prevalence of conjunctivitis correlated with disease 
severity: 3% of conjunctivitis in severe patients in contrast 
to 0.7% in non-severe patients.12
Overall, the most common ocular manifestation of 
SARS-CoV-2 infection is conjunctivitis or conjunctivitis- 
like signs and symptoms, which is similar to SARS-CoV 
and HCoV-NL63.13–16 Conjunctivitis may be unilateral or 
bilateral.9 Two case reports describe the presence of pseudo-
membranes among severe cases of conjunctivitis. Salducci 
et al reported one COVID-19 patient with pseudomembranes 
of fibrin, inflammatory cells, and enlarged preauricular and 
submaxillary lymph nodes.17 Navel et al reported one case 
with conjunctival pseudomembranes associated with pete-
chial and tarsal hemorrhages.18 Cheema et al reported 
a case of keratoconjunctivitis with corneal subepithelial infil-
trates and overlying epithelial defects.19
Other ocular manifestations include photophobia,20 red-
ness, ocular secretions, chemosis, itching, foreign body sen-
sation, dry eyes, follicular conjunctivitis, and episcleritis21 
(summarized in Table 1). Importantly, none of the studies 
reported any associated changes in visual acuity of COVID- 
19 patients with ocular manifestations.9,21–23
There has been only one study showing retinal changes 
in COVID-19 patients.23 Marinho et al examined 12 
COVID-19 patients and found that all of them displayed 
hyper-reflective changes in retinal ganglion cell and inner 
plexiform layers binocularly using OCT. Four patients had 
cotton wool spots and microhemorrhages but no signs of 
intraocular inflammation. Despite OCT changes in the 
retina, no visual acuity nor pupillary reflex changes was 
found.
The timing and duration of ocular manifestations of 
COVID-19 also vary. In several cases, conjunctivitis- 
related discomfort was part of the initial chief 
complaint.19,22,24,25 One patient self-reported having 4 days 
of conjunctivitis and 3 days of fever prior to admission.22 
Another case report described a man who presented with 
unilateral eyelid edema and moderate conjunctival hypere-
mia but then developed headache, fever, cough, and dyspnea 
hours after ocular discomfort.24 Hong et al studied 64 
COVID-19 patients, and found that 6 of 15 conjunctivitis 
patients showed ocular signs and symptoms prior to COVID- 
19 related fever or respiratory symptoms.25 In a case report, 
Cheema et al found that a patient presented with keratocon-
junctivitis 5 days prior to testing positive for COVID-19 via 
nasopharyngeal swab.19
In contrast, a few studies showed that some COVID-19 
patients developed ocular manifestations several days after 
the onset of respiratory illness.9,26 Among a group of 18 
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Table 1 Summary of Ocular Manifestations and Detection of SARS-CoV-2 RNA on Ocular Surface





Ocular Signs and Symptoms
Salducci et al17 Case report Positive NR Photophobia, redness, serous secretions, chemosis, 
pseudomembranes of fibrin, inflammatory cells, 
preauricular and submaxillary LAD
Mendez Mangana 
et al21
Case report Positive NR Nodular episcleritis
Navel et al18 Case report Positive NR Tarsal pseudomembranes, petechial/tarsal hemorrhages
Hu et al33 Case report Positive Positive Left lacrimal duct obstruction and mild tearing
Cheema et al19 Case report Positive Positive Keratoconjunctivitis
Chen et al37 Case report Positive Positive Bilateral acute follicular conjunctivitis
Daruich et al24 Case report Positive NR Unilateral eyelid edema, conjunctival hyperemia
Loon et al27 Case series 0 of 36 (0%) 3 of 36 (8%) NR
Marinho et al23 Cross sectional NR NR Retinal findings (hyper-reflective lesions at the level of 
ganglion cell and inner plexiform layers more prominent 
than at the papillomacular bundle, cotton wool spots, 
microhemorrhages)
Chen et al26 Cross sectional 27 of 535 (5%) NR Conjunctival congestion
Guemes-Villahoz 
et al9
Cross sectional 18 of 689 (3%) 1 of 689* (6%) Unilateral and bilateral conjunctivitis, redness, ocular 
secretions
Zhang et al22 Cross sectional 2 of 72 (3%) 1 of 72* (0.1%) Conjunctivitis with conjunctival congestion and watery 
discharge
Zhou et al30 Cross sectional 8 of 121 (7%) 3 of 121 (2%) Itching, redness, tearing, discharge, foreign body sensation
Ceran et al20 Cross sectional 20 of 93 (22%) NR Hyperemia, epiphora, ocular secretions, chemosis, 
follicular conjunctivitis, episcleritis, photophobia
Xie et al35 Cross sectional NR 2 of 33 (6%) NR
Wu et al29 Cross sectional 12 of 38 (32%) 2 of 38 (5%) Conjunctivitis, conjunctival hyperemia, chemosis, 
epiphora, and increased secretions
Seah et al34 Prospective 0 of 17 (0%) 0 of 17**(0%) NR
Xia et al28 Prospective 1 of 30 (3%) 1 of 30* (3%) Conjunctivitis, conjunctival congestion, ocular secretions
Zhou et al30 Prospective 1 of 67 (1%) 3 of 67 (4%) Conjunctivitis
Hong et al25 Retrospective 15 of 56 (27%) 1 of 56 (2%) Sore eyes, itching, foreign body sensation, tearing, 
redness, dry eyes, ocular secretions, floaters, 
conjunctivitis
Guan et al1 Retrospective 9 of 1099 (0.8%) NR Conjunctival congestion
Loffredo et al12 Meta-analysis 1% NR Conjunctivitis
Lawrenson et al11 Meta-analysis <4% 3% Conjunctivitis
Ulhaq et al10 Meta-analysis 42 of 735 (5.5%) NR Conjunctivitis
Notes: *Sampled only symptomatic patients. **Schirmer test strips. 
Abbreviation: NR, not reported.
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COVID-19 patients with conjunctivitis, the mean onset of 
ocular manifestations was 8 days (ranging from 1–24 
days) after the onset of COVID-19 symptoms.9 Another 
study of 27 patients reported that only 4 of the COVID-19 
patients presented ocular conjunctival congestion as the 
initial symptom while the other 23 patients developed 
conjunctival congestion between 0–28 days after non- 
ocular COVID-19 symptom onset.26
The Role of the Eye in SARS-CoV-2 
Transmission
The ocular system may play three roles in viral transmis-
sion. First, the virus may be shed from ocular surface 
secretions and/or tears which facilitates viral spreading. 
Second, the initial viral infection may occur at ocular 
surface tissues. Third, the virus may spread to the respira-
tory system of the same individual with the ocular system 
acting as a conduit.
The Potential of Viral Shedding from 
Ocular Surface
It is postulated that ocular surface secretions and/or tears 
are the potential sources of SARS-CoV-2 transmission. 
Viral RNA was detected in tear samples from 2003 
SARS outbreak patients using RT-PCR.27 In Singapore, 
SARS-CoV was detected in tears from 3 of 8 probable 
SARS-CoV infected patients.27 Similarly, many studies 
also showed SARS-CoV-2 RNA in ocular samples as 
described previously. However, the SARS-CoV-2 viral 
detection rate of conjunctival swabs is overall low. In 
one meta-analysis, the pooled rate of viral RNA detection 
was estimated to be 3%.11 In another meta-analysis, Ulhaq 
and Soraya found that the specificity of SARS-CoV-2 viral 
detection using conjunctival swabs was 100% but the 
sensitivity was only 0.6% compared to nasopharyngeal 
swabs.10 Similarly, our literature review showed that ocu-
lar viral detection rate ranged from 0% to 8% among 
confirmed COVID-19 patients (Table 1).
Surprisingly, detection of SARS-CoV2 RNA is not 
always associated with ocular manifestations.22,28–31 Xia 
et al collected conjunctival swabs from 30 confirmed 
COVID-19 patients, among whom only 1 patient was 
SARS-CoV-2 viral RNA positive and that patient was the 
only individual with conjunctivitis.28 In contrast, Wu et al 
reviewed 12 COVID-19 patients with conjunctivitis, and 
only 2 patients were viral positive for their conjunctival 
swabs.29 Zhang et al also reported that one of the two 
COVID-19 patients with conjunctivitis was SARS-CoV-2 
RNA positive in the tear sample.22 Zhou et al studied 
conjunctival swabs from 121 COVID-19 patients, among 
whom there were 8 patients with ocular symptoms.30 
However, SARS-CoV-2 RNA was detected in the conjunc-
tival swab in only 1 of the 8 patients, and that patient was 
a severe/critical case.30 However, among the other 113 
patients without any ocular symptoms, 2 were viral RNA 
positive in their conjunctival swabs.30 In another study 
with 67 COVID-19 patients, Zhou et al found positive 
SARS-CoV-2 RNA test results in 1 patient and probable 
positive results in 2 patients, but none of the 3 patients had 
ocular complaints.31 There was only 1 patient with ocular 
manifestations in the same study but her conjunctival swab 
test result was negative.
It is not yet clear why there is an inconsistency between 
viral detection and ocular manifestations. Some studies sug-
gested that the possibility of viral shedding in COVID-19 
patients is relatively low compared to the respiratory 
system.26,32 One potential explanation is that the virus may 
be washed out or significantly diluted by the tear film, which 
could lead to low detection rates.25 Interestingly, Hu et al 
reported one COVID-19 patient who showed persistently 
positive RNA results in conjunctival swabs for an additional 
2 weeks despite the convalescence of symptoms and negative 
nasopharyngeal swabs.33 This patient had lacrimal duct 
obstruction, suggesting less drainage through the nasolacri-
mal duct which could allow the virus to accumulate in his 
conjunctival sample.
Pre-existing ocular surface diseases may also affect viral 
detection.25 Hong et al studied 56 COVID-19 patients and 
15 of them had obvious ocular symptoms.25 Among all 56 
patients, only 1 patient showed positive SARS-CoV-2 in 
conjunctival swab. This patient had conjunctivitis as well as 
a history of prior pterygium surgery. The authors suggested 
that the patient’s pre-existing ocular surface disease might 
have compromised the ocular defense mechanism which 
could predispose him to viral retention and detection.
Although these clinical studies provided insight into 
SARS-CoV-2 shedding, they have some limitations:
1) The majority of studies included only hospitalized 
patients, which is likely to introduce selection bias. Severe 
COVID-19 cases are more likely to have ocular manifesta-
tions or be evaluated for their ocular complaints.12 For 
example, COVID-19 patients or suspects with only mild 
respiratory or ocular symptoms might not seek medical 
assistance, especially if their visual function was not 
impaired.
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2) Another limitation is the heterogeneity in sample 
collection methods. Not all the studies utilized conjuncti-
val swabs, which might produce different results for viral 
detection. For example, one study utilized Schirmer’s test 
strips,34 which collected mainly tears as opposed to both 
exfoliated cells and tears in conjunctival swabs.35 Viral 
loads may differ between tears and ocular surface tissues, 
which could affect the ability for the conventional RT-PCR 
assay to detect SARS-CoV-2 RNA. In addition, appropri-
ate swab materials should be used to facilitate viral RNA 
detection. For nasopharyngeal swabbing, the World Health 
Organization (WHO) recommends using synthetic fiber 
swabs with plastic shafts but not calcium alginate swabs 
or those with wooden shafts because they may contain 
substances that could inactivate the virus or interfere 
with the PCR test (https://www.cdc.gov/coronavirus/2019- 
ncov/lab/guidelines-clinical-specimens.html).
Additionally, not all studies tested ocular samples for all 
subjects (Table 1). Since we now know that there is 
a significant proportion of RNA positive individuals with-
out ocular manifestations, the detection rate might have 
been different. Other differences in sample collection tech-
niques included the decision to use topical anesthetics dur-
ing sampling as well as the sampling of one or both eyes.
3) The timing of sample collection may also affect 
results. Recent SARS-CoV-2 studies focusing on the 
upper respiratory tract showed that 1) viral loads in naso-
pharyngeal specimens peaked at 2–3 days after the onset of 
symptoms, and 2) viral loads between symptomatic and 
asymptomatic patients are equivalent.32,36 However, 
whether these findings apply to tear samples is unknown. 
Some studies suggest that earlier sampling may yield more 
positive results.27,35,37 For example, during the 2003 SARS 
outbreak, one study conducted in Singapore sampled 8 
patients and detected 3 positive cases of SARS-CoV via 
conjunctival swab.27 The 3 positive cases had a mean sam-
pling time of 4.0 days since symptom onset, whereas the 5 
negative had a mean sampling time of 19.4 days. Similarly, 
in a cross sectional study of 33 COVID-19 patients, most of 
the ocular samples were collected more than 7 days of 
symptom onset, and Xie et al found only 2 cases with 
positive ocular SARS-CoV-2 RNA results.35 However, 
one case report described an individual who demonstrated 
positive conjunctival viral RNA at 13, 14, and 17 days after 
symptom onset, and his conjunctival viral RNA turned 
negative on day 19.37 At this time, it is still difficult to 
determine the optimal time window to detect SARS-CoV 
-2 on the ocular surface. There are multiple factors to 
consider such as self-reporting of symptoms, duration of 
symptoms, and fluctuation in viral load in ocular tissues.
The Potential of Contracting SARS-CoV-2 
via the Eye
A major concern for public health as well as ophthalmolo-
gists is whether ocular exposure to SARS-CoV-2 may be 
a route of infection. There are a few reports suggesting this 
possibility.19,22 Lu et al reported that a respiratory specialist 
who was inspecting clinics within the Wuhan region, had 
complaints of redness in his left eye several days prior to 
developing respiratory symptoms and later he was tested 
positive for SARS-CoV-2.38 He might have contracted 
SARS-CoV-2 via the eye since he wore N95 masks but did 
not wear protective eyewear. Zhang et al reported that an 
emergency department nurse in Wuhan China with inade-
quate eye protection while working with COVID-19 suspects 
had red and teary eyes from days 1–4 of disease onset.22 
Although her conjunctival and nasopharyngeal swabs were 
both negative at day 10, she later developed fever and pneu-
monia and was later confirmed to have COVID-19.
The mechanism of SARS-CoV-2 infection of the ocular 
tissue, however, is still unclear. The membrane-associated 
angiotensin-converting enzyme 2 (ACE2) is believed to be 
the primary receptor/entry protein for coronaviruses including 
SARS-CoV and SARS-CoV-2,39 while MERS relies on the 
DPP4 receptor.40,41 SARS-CoV-2 binds to ACE2 using its 
spike transmembrane protein, is processed by serine protease 
TMPRSS2, and enters host cells during early infection.5,39
It is well-established that ACE2 is highly expressed in 
the lung and therefore SARS-CoV and SARS-CoV-2 are 
primarily associated with respiratory system diseases. Our 
current knowledge of SARS-CoV-2 infection mainly is 
based on research of the respiratory system, but recent 
literature suggested that the ocular system shares the 
same infection mechanism.42,43 Jiang et al developed 
human ACE2 receptor transgenic mice and infected them 
with SARS-CoV-2.42 They found that while most viruses 
were found in the lungs, low levels of viruses were also 
detected in the heart, brain, and eye, suggesting a tropism 
of SARS-CoV-2 for ocular tissues. In addition, Hui et al 
found that locally isolated SARS-CoV-2 viruses were able 
to infect human conjunctiva explants.43 These studies sup-
port the possibility of entry of SARS-CoV-2 via the eye.
Since ACE2 is the key receptor for SARS-CoV-2 infection, 
its ocular expression is of particular importance. Previous 
studies showed the expression of RAS system components 
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and ACE2 in the posterior segment such as the retina and 
choroid.44 Recent studies have attempted to determine ACE2 
in ocular surface tissues, such as the conjunctiva and cornea, 
which are exposed to the external environment and are poten-
tial entry points for SARS-CoV-2 infection. Sungnak et al 
compared the expression of ACE2 among multiple tissues 
and organs and found that ACE2 is expressed in corneal 
epithelial cells.45 Zhou et al had similar findings using post- 
mortem eyes and surgical specimens to study ACE2.46 They 
found that both ACE2 and TMPRSS2 are significantly 
expressed and localized in corneal epithelial and endothelial 
tissues.
In contrast to the cornea, current studies showed that the 
expression of ACE2 in the conjunctiva is low.47–49 Lange et al 
used RNA sequencing (RNAseq) to determine ACE2 in 38 
conjunctival samples from 38 patients.47 The authors found no 
substantial expression of ACE2 or other co-receptors 
(TMPRSS2, ANPEP, DPP4, and ENPEP) at mRNA levels 
in conjunctival samples. Immunohistochemistry staining 
showed similar results. Ma et al studied human conjunctival 
and pterygium cell lines, and the authors found that a) ACE2 
was expressed in only 2 of 3 conjunctival and pterygium cell 
lines, and b) TMPRSS2 was expressed in 1 of 3 pterygium cell 
lines but none of the 3 conjunctival cell lines.48 Leonardi et al 
used RNAseq and microarray to study 18 healthy conjunctival 
samples and 6 ex vivo healthy cornea samples.49 They found 
weak ACE2 expression and intermediate TMPRSS2 expres-
sion in the conjunctiva and cornea.
There are several potential protective factors that may 
inhibit ocular infection by SARS-CoV-2. We believe that low 
ACE2 expression level in the conjunctiva as well as constant 
flushing of ocular secretions and tears may play a role. Also, 
lactoferrin and secretory IgA in tears may inhibit SARS-CoV 
-2 infection. Notably, Lang et al found that lactoferrin inhi-
bits SARS-CoV binding in a dose-dependent manner by 
interfering with viral attachment to heparan sulfate proteo-
glycans, an important anchoring site that assists in the initial 
stage of the virus binding the cell surface.50 Although similar 
studies on SARS-CoV-2 have not been done, lactoferrin is 
very likely to inhibit SARS-CoV-2 since SARS-CoV-2 
shares similar infection mechanisms with SARS-CoV.
The Potential Role of Ocular Tissues in 
Respiratory Tract Infection
Another potential role of the eye in viral transmission of 
SARS-CoV-2 could be as a transport conduit to respiratory 
tract tissues. When ocular secretions and tears are drained 
through the nasolacrimal duct to the inferior meatus of the 
nose, viral particles may be transported from the ocular 
surface to the airway tissue causing respiratory infection 
and diseases.51 Recent studies have indicated that there is 
strong ACE2 expression specifically in nasal epithelial 
cells45 which would be in direct contact with draining 
ocular secretions and tears. However, further studies are 
needed to evaluate this possibility as a route of infection.
Conclusions and Future Studies
The development of effective therapies and vaccines 
against the COVID-19 pandemic is still rapidly evolving. 
Therefore, understanding the possible transmission routes 
and mechanisms of SARS-CoV-2 infection is of utmost 
importance. Current studies suggested that the eye is 
a potential route for SARS-CoV-2 transmission and infec-
tion. However, the risk of viral spreading via ocular secre-
tions and tears or contracting an infection via the eye is 
likely low comparing to other routes of infection such as 
respiratory tissues. This is supported by both clinical stu-
dies and research findings including low rates of viral 
RNA detected in conjunctival swabs and epidemiologic 
studies showing a relatively low likelihood of developing 
ocular manifestations or infection. Fortunately, there is no 
evidence showing that SARS-CoV-2 affects visual acuity 
or other visual functions. However, appropriate precau-
tions and use of personal protective equipment for the 
eyes such as goggles and face shields should still be 
employed at this time. Until more conclusive results are 
available, preventative measures should reflect the most up 
to date evidence. We believe that future studies are needed 
to determine:
1. The potential for viral shedding in tears or secre-
tions of asymptomatic carriers since they play an 
important role in the pandemic. It has already been 
shown that COVID-19 patients without any ocular 
manifestations shed detectable levels of virus but 
the study of asymptomatic carriers is not yet 
available.
2. A standardized method for collecting ocular samples 
for SARS-CoV-2 testing. Heterogeneity in testing 
techniques are an unnecessary impact on clinical and 
research outcomes. A standardized approach for sam-
ple collection as well as a wider range of sampling 
time points would provide insightful information.
3. Whether ocular surface tissues can be directly 
infected by SARS-CoV-2 using in vivo models, 
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ideally primate models. Animal models would pro-
vide pertinent information, such as minimum viral 
titer and the duration from infection to the onset of 
ocular symptoms/signs.
4. The risk of SARS-CoV-2 exposure during ocular 
surgeries. Napoli et al summarized potential risks 
and potential solutions to minimize viral exposure 
for eye surgeons.52 The authors emphasized the 
possibility of generating bioaerosols during lacrimal 
procedures. More research is needed to determine 
these risk factors and find out effective strategies to 
protect practitioners. In addition, there have been no 
studies to determine if the aqueous humor could 
contain SARS-CoV-2. Different from tears, aqueous 
humor is not secreted in normal individuals. 
However, for glaucoma patients who have received 
trabeculectomy, drainage valves, and similar proce-
dures, their aqueous humor may be a potential 
source of viral transmission.
5. The association between uveitis and SARS-CoV-2. 
A recent study showed that IFN induces ACE2 in 
human airway epithelium.53 Since IFN is used to treat 
certain uveitis, it may also increase the chance of viral 
contraction and/or spreading among these patients.
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